Adipotide is an experimental peptidomimetic compound designed to induce targeted apoptosis of adipose tissue vasculature for weight reduction in obesity. It consists of a prohibitin-targeting peptide coupled to a pro-apoptotic peptide sequence. Adipotide is not FDA-approved and remains in investigational status, with clinical development discontinued due to safety concerns including renal toxicity.

AOD 9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176-191. Originally developed for its potential anti-obesity and fat-reducing properties, this peptide is not FDA-approved for any medical indication and remains an investigational compound. It is primarily encountered in research settings and unregulated wellness markets.

Ara-290 is an investigational peptide compound derived from erythropoietin that selectively activates the innate repair receptor without erythropoietic activity. It is being studied primarily for the treatment of neuropathic conditions, including diabetic neuropathy, sarcoidosis-associated small fiber neuropathy, and diabetic macular edema. Ara-290 is not currently FDA-approved and remains in clinical development.

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It is currently an investigational compound not approved by the FDA for any clinical indication, though it has been extensively studied in preclinical models for tissue healing, gastrointestinal protection, and various regenerative applications. BPC-157 is marketed through compounding pharmacies and research chemical suppliers, but lacks regulatory approval for human therapeutic use.

Cagrilintide is a long-acting amylin analogue peptide currently in clinical development for the treatment of obesity and type 2 diabetes mellitus. It is designed to mimic the effects of the naturally occurring hormone amylin, which regulates appetite and gastric emptying. As of current data, cagrilintide is investigational and has not yet received FDA approval, though it is being evaluated in multiple Phase 2 and Phase 3 clinical trials, often in combination with GLP-1 receptor agonists.

Cagrisema is an investigational fixed-ratio combination peptide therapy comprising semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analogue). It is being developed for the treatment of type 2 diabetes mellitus and obesity, administered as a once-weekly subcutaneous injection. As of current data, Cagrisema is in late-stage clinical development and has not yet received regulatory approval from the FDA or other major regulatory agencies.

CJC-1295 (also known as MOD GRF 1-29 or DAC:GRF) is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate growth hormone secretion from the pituitary gland. This peptide compound is not FDA-approved and is currently available only through research channels and compounding pharmacies, primarily used in investigational settings for conditions involving growth hormone deficiency, body composition disorders, and age-related decline in GH secretion.

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an investigational peptide-derived compound that acts as a potent hepatocyte growth factor (HGF) modulator with potential cognitive-enhancing properties. Currently, dihexa is not FDA-approved for any indication and remains in experimental stages of development, primarily being investigated for potential treatment of neurodegenerative conditions and cognitive impairment.

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Originally isolated from rabbit cerebral venous blood during sleep, DSIP has been investigated for its potential effects on sleep regulation, stress response, and neuromodulation. It is not FDA-approved and remains an investigational compound with limited regulatory status in most jurisdictions.

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide that stimulates growth hormone (GH) release from the pituitary gland by acting as a ghrelin receptor agonist. It is primarily used in research settings and for diagnostic growth hormone stimulation testing. GHRP-2 is not FDA-approved for therapeutic use in the United States and remains an investigational compound.

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates growth hormone (GH) release from the pituitary gland through ghrelin receptor activation. It is not FDA-approved for clinical use in the United States and is primarily used in research settings, though it has been explored for potential applications in growth hormone deficiency, aging-related conditions, and body composition optimization. GHRP-6 is classified as a research peptide and is not approved for human therapeutic use by regulatory agencies.

Glow is a peptide-class compound that appears to be associated with multiple dermatological and cosmetic applications based on the extracted data, though the specific molecular structure is not clearly defined in the provided information. The extracted data suggests primary uses in sun protection, skin aging prevention, and various cosmetic dermatology applications. Regulatory status and FDA approval information are not clearly specified in the available documentation.

Glutathione (GSH) is a tripeptide antioxidant composed of glutamic acid, cysteine, and glycine that plays a critical role in cellular defense against oxidative stress. It is used therapeutically in various formulations (oral, intravenous, subcutaneous, inhalation) for conditions ranging from respiratory diseases to chemotherapy-induced neuropathy prevention. Glutathione is available as both prescription medications and dietary supplements, with regulatory status varying by formulation and intended use.

Gonadorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) used primarily in veterinary medicine for treating ovarian follicular cysts and synchronizing estrous cycles in cattle. In human medicine, it has limited diagnostic applications for evaluating pituitary gonadotropin function. The compound is FDA-approved for veterinary use under various brand names including Cystorelin, Fertagyl, OvaCyst, Factrel, and GONAbreed.

Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone peptide used primarily in reproductive medicine for ovulation induction, assisted reproductive technology (ART), and treatment of hypogonadotropic hypogonadism. It is FDA-approved for multiple indications including triggering final oocyte maturation in controlled ovarian stimulation, treating cryptorchidism in pediatric patients, and inducing testosterone production in hypogonadal males. hCG is available as a prescription medication administered via subcutaneous or intramuscular injection.

KPV is a tripeptide consisting of lysine-proline-valine, derived from the C-terminal sequence of alpha-melanocyte stimulating hormone (α-MSH). It is an investigational anti-inflammatory peptide being studied for its potential therapeutic applications in inflammatory bowel disease, wound healing, and various inflammatory conditions. KPV is not currently FDA-approved and remains in experimental stages of development.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for treatment of type 2 diabetes mellitus (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is available as a once-weekly subcutaneous injection (Ozempic 0.25-2 mg, Wegovy 0.25-2.4 mg) and as an oral tablet (Rybelsus 3-14 mg daily), representing the first oral GLP-1 agonist approved for clinical use.

Sermorelin (GEREF) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the naturally occurring 44-amino acid GHRH peptide. It is used diagnostically to assess growth hormone secretory capacity and has been investigated for therapeutic applications including growth hormone deficiency, HIV-associated lipodystrophy, and age-related conditions. The original FDA-approved formulation (GEREF) was discontinued in the United States, though sermorelin remains available through compounding pharmacies for off-label uses.

Tirzepatide (MOUNJARO, ZEPBOUND) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for the treatment of type 2 diabetes mellitus (as MOUNJARO) and chronic weight management in adults with obesity or overweight with weight-related comorbidities (as ZEPBOUND). This first-in-class dual agonist represents a significant advancement in metabolic disease management, demonstrating superior efficacy in glycemic control and weight reduction compared to selective GLP-1 receptor agonists.

Wolverine is an investigational peptide compound currently under clinical evaluation for multiple therapeutic indications. Based on available clinical trial data, it is being studied across diverse conditions including autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease), dermatological conditions (atopic dermatitis, hidradenitis suppurativa, vitiligo, prurigo nodularis), hematologic malignancies (diffuse large B-cell lymphoma), and cardiovascular applications (coronary artery disease with calcified lesions, in-stent restenosis). The compound has not yet received regulatory approval from the FDA or other major regulatory agencies and remains in various phases of clinical investigation.